SEOUL, South Korea, June 4 — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that it has raised approximately KRW 110 billion through a third-party allotment of newly issued common shares to strategic investors. The investment was jointly made by BOLD, L’Oréal’s corporate venture capital fund, and Weiss Asset Management LP, a U.S. asset management firm.
BOLD is L’Oréal’s venture investment arm that backs promising beauty brands, biotech, and tech companies, especially those with disruptive innovation potential. The U.S. asset manager is also a key global investor in OliX and participated in this round following its investment in August 2025.
With the newly secured funds, the company intends to advance its ongoing siRNA-based projects in several therapeutic areas, including skin- and hair-related projects. The company also expects the investment to further strengthen its strategic partnership with L’Oréal. Through this, the company aims to reinforce its research foundation and accelerate development progress.
Guive Balooch, Global Managing Director of Open Innovation and Augmented Beauty at L’Oréal, said, “We are excited to strengthen our scientific partnership with OliX with an equity investment by BOLD. This strategic collaboration combines OliX’s world-class siRNA platform capabilities with L’Oréal’s century-long commitment to beauty innovation and expertise across biology, tech, and formulation. We are convinced that together we’ll accelerate in creating the future of beauty for the benefit of consumers globally with new levels of performance backed by advanced biology and robust scientific proof.”
Dong Ki Lee, CEO of OliX Pharmaceuticals, said, “We are delighted to secure funding from BOLD and Weiss.” He added, “Their support reflects strong confidence in our partnership and shared vision for innovation. The joint participation of a global strategic partner and a major investor reflects strong market confidence in the company’s technological competitiveness and future growth potential.”